FDA Review of Varenicline and Risk of Cardiovascular Adverse Events

Published Online: Wednesday, December 19, 2012
Follow Pharmacy_Times:
This podcast, from the Centers for Disease Control and Prevention, discusses a drug safety communication released by the FDA on December 12, 2012, regarding the risk of cardiovascular adverse events associated with the smoking-cessation drug varenicline (Chantix).
 
To download the podcast, click here.
Related Articles
The Advisory Committee on Immunization Practices of the US Centers for Disease Control and Prevention has voted to recommend meningococcal group B vaccination for adolescents and young adults.
The FDA today approved The Medicines Company’s cangrelor (Kengreal), an intravenous antiplatelet medication that can prevent blood clots from forming in the coronary arteries.
Women with diabetes have a considerably higher risk of developing coronary heart disease than men with diabetes.
Many common Cardiovascular Disease risk factors, such as hypertension, high cholesterol, type 2 diabetes, and thrombosis, are often experienced by women after a spontaneous preterm delivery.
Latest Issues
$auto_registration$